Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
November 07, 2024 08:30 ET
|
Mustang Bio, Inc.
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
October 24, 2024 14:10 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 21, 2024 16:01 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 20, 2024 08:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., June 20, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
June 17, 2024 08:30 ET
|
Mustang Bio, Inc.
Overall response rate of 90% in cohort with durable responses observed; one patient remains in complete remission at 31 months All patients were heavily pretreated/refractory to BTK inhibitors, and...
Mustang Bio Announces Pricing of $4 Million Public Offering
April 29, 2024 20:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
March 28, 2024 09:00 ET
|
Mustang Bio, Inc.
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the fourth...
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 11, 2024 16:05 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
March 07, 2024 07:30 ET
|
Mustang Bio, Inc.
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 11, 2024 08:30 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...